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Background: GTP cyclohydrolase 1 (GTP-CH1), the rate-limiting enzyme in the synthesis of tetrahydrobiopterin
(BH4), encoded by the GCH1 gene, has been implicated in the development and maintenance of inflammatory pain
in rats. In humans, homozygous carriers of a “pain-protective” (PP) haplotype of the GCH1 gene have been
identified exhibiting lower pain sensitivity, but only following pain sensitisation. Ex vivo, the PP GCH1 haplotype is
associated with decreased induction of GCH1 after stimulation, whereas the baseline BH4 production is not affected.
Contrary, loss of function mutations in the GCH1 gene results in decreased basal GCH1 expression, and is associated
with DOPA-responsive dystonia (DRD). So far it is unknown if such mutations affect acute and inflammatory pain.
Results: In the current study, we examined the involvement of the GCH1 gene in pain models using the
hyperphenylalaninemia 1 (hph-1) mouse, a genetic model for DRD, with only 10% basal GTP-CH1 activity compared
to wild type mice. The study included assays for determination of acute nociception as well as models for pain after
sensitisation. Pain behavioural analysis of the hph-1 mice showed reduced pain-like responses following intraplantar
injection of CFA, formalin and capsaicin; whereas decreased basal level of GTP-CH1 activity had no influence in
naïve hph-1 mice on acute mechanical and heat pain thresholds. Moreover, the hph-1 mice showed no signs of
motor impairment or dystonia-like symptoms.
Conclusions: In this study, we demonstrate novel evidence that genetic mutations in the GCH1 gene modulate
pain-like hypersensitivity. Together, the present data suggest that BH4 is not important for basal heat and
mechanical pain, but they support the hypothesis that BH4 plays a role in inflammation-induced hypersensitivity.
Our studies suggest that the BH4 pathway could be a therapeutic target for the treatment of inflammatory pain
conditions. Moreover, the hph-1 mice provide a valid model to study the consequence of congenital deficiency of
GCH1 in painful conditions.
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Chronic pain is a severe and common healthcare prob-
lem that affects millions of people worldwide. In spite of
a number of analgesics available for pain therapy, pain
often remains inadequately treated in many patients and
represents a major cause of suffering and reduced qual-
ity of life [1]. One of the reasons for the difference in
success of pharmacologic pain treatment rely on the dif-
ferent genetic disposition of patients to develop pain or
to respond to analgesics [2].
The GCH1 gene is one of few genes reported to be
involved in the modulation of pain sensitivity in humans
[3-5]. The gene codes for the enzyme guanosine tri-
phosphate cyclohydrolase 1 (GTP-CH1), the first and
rate-limiting enzyme in the de novo synthesis of 5,6,7,
8-tetrahydrobiopterin (BH4) (see Additional file 1). BH4
is an essential cofactor for phenylalanine, tyrosine and
tryptophan hydroxylases and for all isoforms of nitric
oxide synthase (NOS). Hence, BH4 regulates the synthe-
sis of catecholamines, serotonin and nitric oxide (NO)
(see Additional file 1), all involved in pain signalling [6].
In 2002, Costigan and colleagues made a systematic
search for pain-related genes using microarray based
gene expression analysis [7]. This led to the discovery of
two genes both involved in BH4 biosynthesis; the GCH1
gene and the gene for sepiapterin reductase (SR) (see
Additional file 1). Both genes were upregulated in dorsal
root ganglion (DRG) following peripheral axotomy in
rats. In a follow-up study, BH4 synthesis was found to
be upregulated in primary sensory neurons after periph-
eral inflammation and nerve injury [4]. Inhibition of
BH4 synthesis with the prototypic GTP-CH1 inhibitor
2,4-diamino-6-hydroxypyrimidine (DAHP) reduced the
nociceptive responses in rodent models of neuropathic
and inflammatory pain accompanied by reduced BH4
concentrations in DRGs, whereas intrathecal injection of
BH4 induced pain in naïve rats [4]. Furthermore, in
humans a particular haplotype of the GCH1 gene identi-
fied as “pain protective”(PP) was found to be associated
with reduced pain sensitivity in healthy subjects as well
as persistent low back pain in patients after discectomy
[3,4], though other research did not confirm this associ-
ation [8]. Recently, downregulation of the GCH1 gene by
adeno-associated virus mediated expression of small
hairpin RNA against GCH1 was shown to reduce neuro-
pathic pain hypersensitivity in rats [9]. Also, inhibition
of GTP-CH1 was found to reduce cancer-induced pain
in mice [10].
In contrast to the GCH1 PP haplotype leading to mod-
erate reduction of BH4 availability and only after stimu-
lation, loss of function mutations in the GCH1 gene
causes reduced basal concentrations of BH4 and is
associated with DOPA-responsive Dystonia (DRD). DRD
is a rare movement disorder that manifest withouthyperphenylalaninemia and the classical clinical charac-
terisation are gait problems due to dystonia, mostly in
the lower extremities with onset in childhood. The
patients respond well to treatment with L-DOPA [11].
The hyperphenylalaninemia 1 (hph-1) mouse is a gen-
etic model for DRD. The mutant mouse was originally
generated by mutagenesis using the sperm mutagen N-
ethyl-N´-nitrosourea [12], and is characterised by a
marked decrease in baseline GCH1 mRNA expression
accompanied by a large decrease in both GTP-CH1
activity and BH4 synthesis. The hph-1 mutation has
been localised to an interval of 1.6-2.8 Mb on chromo-
some 14, containing the murine GCH1 gene [13]. How-
ever, the exact location of the mutation is still undefined.
To the best of our knowledge it has not yet been
reported whether mutations in the GCH1 gene, leading
to profound decrease in basal gene expression, affects
pain sensitivity. Therefore, in the current study we
investigated the hph-1 mice in animal models of acute
and inflammatory pain. We demonstrate that the mutant
mice exhibited reduced inflammatory hypersensitivity,
whereas acute responses to mechanical and heat stimuli
were normal compared to wild type (WT) controls.
Results
Reduced BH4 concentrations in hph-1 mice compared to
WT mice
Plasma BH4 concentrations were examined by high per-
formance liquid chromatography (HPLC) analysis to
evaluate if the hph-1 mice used in this study had the
expected phenotype of reduced BH4 synthesis [14]. The
data showed that heterozygous hph-1 (+,-) mice and
homozygous hph-1 (hph) mice had significantly lower BH4
concentrations compared to WT controls (###p < 0.001,
Figure 1), with +,- mice having intermediate amounts of
BH4. The plasma BH4 values were 472.8 ± 22.14 nmol/L,
259.6 ± 23.92 nmol/L and 108.5 ± 12.42 nmol/L for
WT, +,- and hph mice, respectively. Hence, in plasma,
heterozygous and homozygous animals have approximately
55% and 20% of normal BH4 concentrations, respectively.
Lack of motor impairment and dystonia-like symptoms in
hph-1 mice
As the hph-1 mouse is biochemically a model for DOPA-
responsive dystonia (DRD) [15], the motor behaviour was
examined in this strain. We found that the hph-1 mice
showed no signs of motor impairment nor any abnormal
behaviour when carefully observing the animals. Also in
the wire hanging test, both hph-1 and WT mice were able
to hang upside down for 120 sec, indicating normal
neuromuscular function.
In the rotarod test, +,- and hph mice had no difficulty
maintaining balance on the rod compared to WT mice

























Figure 1 Plasma concentrations of BH4 determined as
biopterin (nmol/L) by reversed-phase HPLC. The BH4
concentration was significantly reduced in both +,- and hph mice
compared to WT mice (###p < 0.001) (n = 6 for WT and +,- mice, and
n = 7 for hph mice). Moreover, hph mice displayed significantly
lower BH4 concentrations compared to +,- mice ($$$p < 0.001). One-
way ANOVA with pair-wise comparisons using the Fisher’s LSD test.











































Figure 2 No motor impairment nor dystonia-like symptoms
were seen in +,- and hph mice. (a) time walking on the rotarod
(sec) and (b) rotation speed (rpm). n = 10, n = 8 and n = 6 for WT,
+,- and hph mice, respectively. No difference in rotarod performance
was found between genotypes (p = 0.92 and p = 0.95, respectively).
One-way ANOVA with pair-wise comparisons using the Fisher’s LSD
test. (c) hind-paw clasping; normal splaying of hind-paws was
observed in hph mice as well as WT mice (not shown). Data are
presented as mean + SEM.
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among genotypes (p = 0.92 and p = 0.95). The WT, +,-
and hph mice stayed on the rotating rod for 197 ±
29 sec, 210 ± 31 sec and 207 ± 18 sec, respectively. In
addition, dystonia-like symptoms were examined by
suspending the animals by their tail for 15 sec, and this
revealed that the mutant mice did not display any hind-
paw clasping (Figure 2c). Overall, these observations
demonstrate that hph-1 mice are not associated with
reduced motor function nor dystonia-like symptoms.
The hph-1 mutants exhibit normal pain behavioural
responses to heat and mechanical stimuli
Acute heat sensitivity was assessed by two different
assays; the hot plate test (Figure 3a) and the Hargreaves
test (Figure 3b). In the hot plate test, the latency time to
respond to noxious heat stimulation was not signifi-
cantly different between hph-1 mice and WT mice at nei-
ther 52°C (WT: 27 ± 1 sec and hph: 23 ± 2 sec, p = 0.13)
nor 55°C (WT: 14.6 ± 0.8 sec, +,-: 15.9 ± 0.9 sec and hph:
15.5 ± 1.1 sec, p = 0.54). In the Hargreaves test, the paw
withdrawal latencies of mutant mice to heat stimulation
was also not different from WT responses (WT: 7.3 ±
0.2 sec, +,-: 7.6 ± 0.4 sec and hph: 7.0 ± 0.3 sec, p = 0.65).
Mechanical sensitivity was examined using the von
Frey and Randall Selitto test (Figure 3c-d). In the von
Frey test, the withdrawal threshold to mechanical stimu-
lation was not significantly different between genotypes
(WT: 0.84 ± 0.06 g, +,-: 0.79 ± 0.04 g and hph: 0.83 ±
0.04 g, p = 0.92). Similarly, the mean weight resulting in
tail withdrawal in the Randall Selitto test was 102.4 ±







































































































Figure 3 Normal behavioural responses to heat and mechanical stimuli were observed in +,- and hph mice. (a) Hot Plate; latency
time to respond by hind-paw licking, lifting or flinching at a plate temperature of 52°C (n = 19) or 55°C (n = 12–17). No significant change was
observed between genotypes (p = 0.13 and p = 0.54, respectively). (b) Hargreaves Test; withdrawal latencies to noxious heat stimuli (n = 7–15).
No change in latency time was found among genotypes (p = 0.65). (c,d) von Frey and Randall Selitto; withdrawal threshold to mechanical
stimulus (n = 10–16 and n = 13–15, respectively). Hph-1 mice exhibited similar mechanical thresholds as WT mice (p = 0.92 and p = 0.68).
Mann–Whitney t-test, two-tailed or one-way ANOVA with pair-wise comparisons using the Fisher’s LSD test. Data are presented as mean + SEM.
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groups (p = 0.68). Together, these behavioural obser-
vations suggest that reduction of BH4 synthesis in hph-1
mice does not seem to change sensitivity to peripherally
applied heat and mechanical stimuli in naïve mice.
Reduced CFA-induced mechanical and heat
hypersensitivity in hph-1 mice compared to WT mice
In the complete Freund’s adjuvant (CFA) model, the
baseline withdrawal thresholds to mechanical stimuli of
naïve mice were not significantly different between
genotypes (0.8 ± 0.07 g, 0.74 ± 0.03 g and 0.65 ± 0.06 g
for WT, +,- and hph mice, respectively. p > 0.05). More-
over, the mean withdrawal latencies to heat stimuli wereCFA - von Frey


























































Figure 4 Reduced hypersensitivity after CFA injection in +,- and hph
injection induced mechanical hypersensitivity in +,- and WT mice, but not
hph mice exhibited heat hypersensitivity after peripheral inflammation (n =
†††p < 0.001 versus baseline values (two-way RM-ANOVA with Fisher’s LSD
in mechanical and heat hypersensitivity was found between hph-1 mice an
using the Fisher’s LSD test (log transformed data). #p = 0.04, unpaired t-tes
± or + SEM.similar in hph mice and WT mice (9 ± 1 sec and 9 ±
1 sec, respectively).
Intraplantar injection of CFA into the hind-paw of
WT mice induced a long-term mechanical hypersensitiv-
ity, starting on day 1 and persisting on day 12 (Figure 4a).
The latter is indicated by reduced withdrawal thresholds
to innocuous mechanical stimulation as compared to
baseline values (***p < 0.001). In mutant mice, CFA
injection evoked reduced withdrawal thresholds of the
affected paw in +,- mice (+p < 0.05, Figure 4a), whereas
almost no effect was observed in homozygous mice. Com-
parison of overall area under the curves (AUCs) revealed a
significantly lower mechanical hypersensitivity of +,- and






































mice. (a,c) Time course of mechanical and heat hypersensitivity. CFA
in hph mice (n = 10–14). In the Hargreaves test, both WT mice and
11–14). WT: ***p < 0.001, +,-: +p < 0.05 and hph: †p < 0.05 and
test). (b,d) Area under curve analysis. A statistical significant difference
d WT mice. ###p < 0.001, one-way ANOVA with pair-wise comparisons
t, two-tailed (log transformed data). Data are presented as mean
Nasser et al. Molecular Pain 2013, 9:5 Page 6 of 14
http://www.molecularpain.com/content/9/1/5Figure 4b). In addition, no statistical significant difference
in pain-like responses was found between +,- and hph
mice (p > 0.05). These results show that in homozygous
mice, mechanical hypersensitivity was almost completely
suppressed throughout the observation period compared
to WT controls, whereas heterozygous mice displayed
intermediate responses to CFA injection (Figure 4a). This
suggests a genotype-dependent anti-hypersensitive effect,
with the largest effect in the homozygous hph-1 mice.
Therefore, in subsequent experiments only WT and hph
mice were tested.
Hind-paw injection of CFA also induced a significant
reduction in paw withdrawal latencies in response to
noxious heat stimuli in WT mice as compared to base-
line values (***p < 0.001, Figure 4c). The heat hypersen-
sitivity began at day 1 and lasted for 6 days after paw
injection. In contrast to mechanical hypersensitivity, heat
hypersensitivity was present in hph mice from 1 to 6 days
after CFA injection (†††p < 0.001 and †p < 0.05). How-
ever, a trend towards faster recovery and less heat hyper-
sensitivity was seen in mutant mice compared to WT
mice by day 4 (Figure 4c). Comparison of AUCs showed
that hph mice exhibited significantly lower heat hyper-
sensitivity than WT controls (#p = 0.04, Figure 4d).
To determine the degree of inflammation, the dorsal-
plantar paw thickness was measured 24 hours after CFA
inoculation (see Additional file 2). Injection of CFA
increased the paw thickness in both genotypes as com-
pared with baseline values (p < 0.001), and the data
showed no difference in paw thickness between WT and
hph mice (p > 0.05), indicating similar peripheral
inflammation.
These data show that BH4 plays an anti-hypersensitive
role in inflammatory pain in particular mechanical sensi-
tivity following peripheral inflammation. For the heat
hypersensitivity, the data suggest that BH4 may modu-
late pain sensitivity. However, this effect does not seem
to be robust.
Reduced acute nociceptive behaviour in response to
formalin injection in hph mice
Spontaneous nociceptive pain behaviours due to chem-
ical stimuli were tested using the formalin test (Figure 5).
Intraplantar injection of 0.5 and 2.5% formalin produced
a biphasic response in both WT mice and hph mice,
characterised by licking and biting the paw, with a first
phase starting immediately after formalin injection and a
second phase that began after 10 min and lasted for
50 min (Figure 5a-b).
Following injection of 0.5% formalin, a significant de-
crease in total time licking and biting the paw was seen in
hph mice in the first phase compared to WT controls (hph:
39 ± 3 sec, WT: 68 ± 12 sec, #p = 0.014, Figure 5c). On ad-
ministration of 2.5% formalin a similar reduction inspontaneous pain behaviour was seen in the first phase
(hph: 63 ± 5 sec, WT: 89 ± 7 sec, #p = 0.012, Figure 5d). Re-
gardless of the intensity of noxious chemical stimulus, no
significant difference in spontaneous pain activity was
found in the second phase between homozygous mutant
mice and WT mice (0.5%: 123 ± 18 sec vs. 144 ± 22 sec, p
= 0.48 and 2.5%: 281 ± 41 sec vs. 304 ± 39 sec, p = 0.69,
Figure 5c-d).
These data demonstrate a significant effect of inherited
BH4 reduction on formalin-evoked spontaneous pain
responses. This was specifically observed in the first
phase, suggesting that BH4 might modulate acute no-
ciception induced by formalin injection.
Reduced capsaicin-induced mechanical hypersensitivity
but not spontaneous pain behaviour in hph mice
compared to WT mice
Intraplantar injections of capsaicin into the hind-paw
evoked an immediate nocifensive behaviour charac-
terised by licking, biting and lifting of the paw (Figure 6a).
The duration of the spontaneous pain activity was not sig-
nificantly different between hph mice and WT mice (45 ±
12 sec vs. 50 ± 11 sec, p = 0.46). In addition, the latency
time to respond in hph mice was also similar to that
observed in WTcontrols (8 ± 2 sec vs. 9 ± 2 sec, p = 1.00).
In the capsaicin test, the baseline withdrawal thre-
sholds to mechanical stimulation of naïve mice were also
similar between genotypes (p = 0.78). The mean with-
drawal thresholds were 1.03 ± 0.09 g and 0.99 ± 0.04 g
for WT mice and hph mice, respectively. Following cap-
saicin injection, mechanical sensitivity was evaluated
within a 60 min observation period. Intraplantar injec-
tion of capsaicin (1 μg/paw) into the hind-paw induced a
substantial mechanical hypersensitivity in both groups at
all time points (WT: ***p < 0.001, hph: †††p < 0.001,
Figure 6c). When comparing the overall AUCs, a signifi-
cant reduction in mechanical hypersensitivity was found
in hph mice compare to WT mice (#p = 0.04, Figure 6d).
At lower concentrations of capsaicin (0.25 and 0.5 μg/
paw) both groups exhibited a clear mechanical hypersen-
sitivity in the injected paw, however at these con-
centrations no difference in mechanical sensitivity was
found between genotypes (p > 0.05, Table 1). Heat sensi-
tivity following capsaicin injection was also examined,
but in this case it was not possible to demonstrate pres-
ence of heat hypersensitivity in neither WT mice nor
hph mice (see Additional file 3).
These data suggest that the effect of the mutation in
hph mice on mechanical sensitivity is dependent on the
intensity of the noxious stimulus induced by capsaicin.
Moreover, the results revealed that reduced BH4 avail-
ability impaired capsaicin-evoked mechanical hypersen-





























































































































































Figure 5 Reduced formalin-induced pain behaviour in hph mice. (a) and (b) time course after paw injection of 0.5 and 2.5% formalin. (c) and
(d) total time licking and biting the paw during 0–10 min (phase 1) and 10–50 min (phase 2). A statistical significant reduction in spontaneous
pain activity of hph mice was seen at both formalin-concentrations in the first phase compared to WT mice (0.5%: #p = 0.014, n = 9 and 2.5%:
#p = 0.012, n = 9). Mann–Whitney t-test, two-tailed. No significant change in pain behaviour between genotypes was found in the second phase
(0.5%: p = 0.48 and 2.5%: p = 0.69). Unpaired t-test, two-tailed. Data are presented as mean ± or + SEM.
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In the current study, we used the hph-1 mouse model
deficient in GTP-CH1 to study the involvement of the
GCH1 gene in acute and inflammatory pain models.
This included assays to determine mechanical and heat
nociception as well as pain-like responses to intraplantar
injection of chemical and inflammatory substances. We
demonstrated that hph-1 mice exhibited reduced mech-
anical and heat hypersensitivity following CFA, and
reduced mechanical hypersensitivity after capsaicin in-
jection compared to WT mice, whereas pain behavioural
responses to heat and mechanical stimuli were normal
in naïve mice.
GCH1 in mechano-and thermosensation
The present findings suggest that processes involved in
the transmission of mechanical and heat stimuli in thenon-sensitised organism are independent of GTP-CH1.
This is consistent with previous studies in human
carriers of the GCH1 PP haplotype, and in rats following
pharmacological inhibition with the GTP-CH1 inhibitor
DAHP [4,5]. In rats, intraperitoneal administration of
DAHP attenuated inflammatory pain behaviours, but it
did not change mechanical and heat pain sensitivity in
naïve animals [4]. Furthermore, differences in pain sensi-
tivity between carriers and non-carriers of the GCH1 PP
haplotype were only observed after local skin inflamma-
tion or capsaicin sensitisation [3,5]. It was proposed that
the reason for this observation is that differences in
GTP-CH1 activity in carriers and non-carriers of the
GCH1 PP haplotype were only seen after stimulation
with LPS [5]. In contrast to the human GCH1 PP haplo-
type, the hph-1 mice have significantly lower GCH1









































Capsaicin - von Frey










































Figure 6 Reduced capsaicin-induced mechanical hypersensitivity in hph mice, but normal spontaneous pain behaviours. (a)
Spontaneous pain responses; total time licking, biting and lifting the paw during 10 min after capsaicin injection (1 μg/paw). No difference was
found between hph mice and WT mice (p = 0.46, n = 7–8). (b) Onset of pain behaviour. No differences in latency time was seen among
genotypes (p = 1.00, n = 7–8). Mann–Whitney t-test, two-tailed. (c) von Frey time course; after capsaicin injection (1 μg/paw) both WT mice and
hph mice developed mechanical hypersensitivity (n = 6–10). WT: ***p < 0.001 and hph: †††p < 0.001 versus baseline values. Two-way RM-ANOVA
with pair-wise comparisons using the Fisher’s LSD test. (d) Area under curve analysis. A statistical significant difference in mechanical
hypersensitivity between hph mice and WT controls was found (#p = 0.04). Mann–Whitney t-test, two-tailed. Data are presented as mean ± or
+ SEM.
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about 10% of the WT mice [16] and in agreement with
this a reduced BH4 concentration in blood was found in
this study (Figure 1). Hence, our results indicate that
even though baseline GTP-CH1 activity is reduced in
hph-1 mice it did not appear to influence mechanical
and heat pain thresholds in naïve mice.GCH1 in acute and inflammatory pain
After CFA injection, the homozygous mice did not de-
velop mechanical hypersensitivity, while heat hypersensi-
tivity was present in the mutant mice. This may suggest
differential contribution of GTP-CH1 in the main-tenance of mechanical and heat hypersensitivity. Several
studies point to the involvement of different mecha-
nisms of mechanical and heat hypersensitivity. Heat
hypersensitivity is thought to be mediated by afferent C-
fibers, whereas mechanical hypersensitivity involves acti-
vation of afferent Aβ-fibers [17]. Also studies using
neuronal NOS knock-out mice reported profound loss
of mechanical hypersensitivity, with no change in sensi-
tivity to noxious heat stimulation [18]. Finally, the lack
of correlation between mechanical and heat hypersensi-
tivity in several pain models suggest that these are
mediated by different neural mechanisms [19].
Following intraplantar formalin injection a significant
reduction in spontaneous pain behaviour in hph mice
Table 1 Mechanical hypersensitivity following intraplantar injection of 0.25-1 μg/paw capsaicin in WT mice and hph
mice
Time of testing (min)
Concentration von Frey (g) Baseline 30 60
0.25 μg/paw
WT mice 0.81±0.04 1.00±0.00 0.49±0.15b 0.39±0.07b
hph mice 0.78±0.04a 1.00±0.00 0.44±0.10a,b 0.47±0.07a,b
0.5 μg/paw
WT mice 0.81±0.08 1.00±0.00 0.26±0.03b 0.28±0.11b
hph mice 0.80±0.10a 1.00±0.00 0.28±0.11a,b 0.26±0.03a,b
1 μg/paw
WT mice 1.03 ± 0.09 1.00±0.00 0.18±0.04b 0.19±0.03b
hph mice 0.99 ± 0.04a 1.00±0.00 0.42±0.10b,c 0.39±0.07b,c
The results are expressed as relative pain behaviour (normalised to the baseline response of each mouse). For 0.25, 0.5 and 1 μg/paw n = 3–6, n = 4 and n = 6–
10, respectively. The letter a, indicates non-significant differences when compared to WT mice (p > 0.05), the letter b, indicates significant differences compared to
baseline, and the letter c, indicates significant differences relative to WT (p < 0.05). Unpaired t-test (two-tailed) or two-way RM-ANOVA with Fisher’s LSD test. Data
is shown as mean ± SEM.
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postulated to involve direct activation of nociceptors by
formalin, probably mediated through chemical stimula-
tion of the transient receptor potential cation channel
subfamily A member 1 (TRPA1) [20,21], whereas phase
2 depends on inflammatory reactions in the peripheral
tissue and/or central sensitisation of spinal cord neurons
[22]. It has been proposed that the second phase results
from the barrage of nociceptor inputs during phase 1
[23], hence in the mutant mice a reduction in pain
behaviour during phase 2 was expected. In addition, our
findings contrast with results from rats following
pharmacological inhibition of GTP-CH1 activity, where
attenuated pain behaviour was seen in both phases [4].
The reason for this discrepancy is not immediately
apparent but it may relate to (i) difference in animal spe-
cies and (ii) difference in the mechanisms following
pharmacological inhibition versus genetic inhibition of
GTP-CH1 activity. It is possible that although the noci-
ceptive inputs from peripheral nerves are attenuated
during phase 1 in the mutant mice, there is an increase
or no change in excitability of spinal cord neurons in the
second phase. Another potential explanation for the
present observation is that sustained peripheral nerve
activity rather than spinal sensitisation drives the noci-
ceptive responses in phase 2. This is supported by previ-
ous studies showing that inhibition of pain responses
during phase 1 with anaesthetics or opioids does not
change the magnitude of nociceptive responses during
phase 2 [24,25]. Nevertheless, the finding that spontan-
eous activity in hph-1 mice was not influenced in the
second phase after injection of both low and high forma-
lin concentrations suggests that at least in hph-1 mice,
changes in GTP-CH1 activity is not critical for the
processes driving the second phase of the formalin test.Tegeder et al., 2006 showed that peripheral inflamma-
tion increased the BH4 concentrations in DRG compared
to that of naïve rats, and that administration of DAHP
reduced this excess BH4 production [4]. Reductions in
BH4 synthesis in hph-1 mice have been shown in several
tissues, including brain, liver and lung [13,26,27], and
GTP-CH1 activity is probably reduced in all tissues where
it is normally expressed. Although the reduction of GCH1
in hph-1 mice have been shown to vary in different brain
structures including dorsal raphe (51%), locus coeruleus
(30%) and substantia nigra (39%), the GCH1 expression
was substantially reduced in all brain areas [28], consistent
with decreased BH4 synthesis in the whole brain [26]. Fur-
thermore, stimulation of cultured mast cells from hph-1
mice with cytokines and administration of LPS increased
the GTP-CH1 activity and BH4 synthesis, respectively.
This indicates that enzyme activity can be induced in mu-
tant mice, but absolute values were always markedly lower
in hph-1 mice than in WT mice [27,29]. Taken together, it
is likely that the reduction of hypersensitivity following
sensitisation is due to lower induction of GCH1 and hence
BH4 in DRG of hph-1 mice compared to WT mice.
It is known that BH4 also contributes to the de-
velopment of other types of pain conditions such as
neuropathic pain and cancer-induced pain. Previous
studies have demonstrated that systemic administration
of DAHP has analgesic properties in three models of
neuropathic pain and in two models of cancer-induced
pain [4,10]. In humans, the GCH1 PP haplotype has
been associated with reduced risk of chronic pain after
discectomy as well as a slow progression of pain in can-
cer patients [4,30]. The findings that inhibition of BH4
synthesis modulates pain sensitivity following inflamma-
tion, nerve injury and cancer imply a common mechan-
ism of action of BH4 in these different pain states.
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The mechanisms leading to pain and the sites of action
of BH4 are still unknown. BH4 is not a neurotransmitter
but a cofactor required for activity of a number of
enzymes, including tyrosine and tryptophan hydroxy-
lases and all isoforms of NOS. Accordingly, BH4
regulates the synthesis of serotonin, NO and catecho-
lamines, all playing a complex role in nociceptive signal-
ling. BH4 may therefore mediate noxious pain responses
through mechanisms involving NO and/or biogenic
amines [4,31]. Previous studies imply that BH4 acts
partly through NO mediated mechanisms as injection of
the GTP-CH1 inhibitor DAHP impaired excess NO
production following nerve injury [4]. The implication of
NO in development and maintenance of hypersensitivity
in response to inflammation is well documented
[18,32,33], and it has been shown that NO plays an es-
sential role in both peripheral [33-36] and central [18]
mechanisms of inflammatory pain. Reduced NOS activ-
ity and NO generation have previously been reported in
hph-1 mice determined in the brain as well as astrocytes
and plasma [26,29,37]. Therefore, the alleviated mechan-
ical hypersensitivity following CFA and capsaicin in-
jection may possibly result from (i) decreased spinal
neuronal NOS activity followed by decreased excess NO
production and/or (ii) reduced NO-mediated peripheral
sensitisation.
Caveats of genetic mouse models
Although the use of genetic mouse models has their
advantages, they are associated with important inherited
caveats that need to be considered when interpreting the
data [38]. As the hph-1 mouse is a mutant model, having
decreased GTP-CH1 activity during the development
and throughout life, the role of BH4 in pain might be
different from the ongoing role in the normal adult
mouse. Therefore, genetic based studies might have
different outcomes compared with pharmacological
downregulation of GTP-CH1 in normal animals. How-
ever, it should be emphasised that this caveat also ap-
plies to humans carrying the GCH1 PP haplotype.
The GCH1 gene may also have multiple roles since it
influences many biological systems. Consequently, dis-
ruption of this gene may have multiple effects unrelated
to nociception such as change in motor function. The
mutation in the hph-1 mice share similar biochemical
features as an autosomal dominantly inherited mutation
in the human GCH1 gene manifested as DRD [15]. DRD
results from a reduction in BH4 biosynthesis and the
prominent phenotype is gait problems due to dystonia
[39]. Therefore, reduced BH4 in mice may also yield
effects on motor behaviour, which can confound the
pain behaviours in these animals. However, hph-1 mice
did not demonstrate any signs of motor impairment nordystonia-like symptoms. Considering these observations,
the differences in pain-related behaviours observed be-
tween hph-1 mice and WT mice are not related to
effects on motor function.
Conclusions
In conclusion, our study supports previous findings that
genetic functionally variants of the GCH1 gene influence
pain sensitivity after sensitisation. Furthermore, it re-
vealed that even profound reduction in basal levels of
GCH1 activity did not affect nociceptive pain in naïve
animals. The hph-1 mice with profound decrease in
GTP-CH1 activity displayed reduced pain-like responses
after peripheral inflammation and sensitisation. As GTP-
CH1 is the rate-limiting enzyme in the synthesis of BH4,
these findings suggests that BH4 plays a role in modulat-
ing inflammatory pain that could be a therapeutic target
to treat inflammatory pain conditions. Moreover, the
hph-1 mouse represents a new model to investigate the
role of congenital GCH1 deficiency in pain.
Methods
Animals
The hph-1 mice have previously been generated and
backcrossed for more than 20 generations into the
C57BL/6JOlaHsd background (Harlan Laboratories, UK)
[13]. Heterozygous male hph-1 (+,-) mice from the
Welcome Trust Center for Human Genetics were
shipped to Taconic Denmark (Ejby, Denmark), where
breeding took place. Initially, male heterozygous mice
were mated with female C57BL/6JOlaHsd mice to pro-
duce heterozygous progeny, and these were then mated
to generate WT, heterozygous and homozygous hph-1
littermates. Later, animals were generated by homozy-
gous breeding, no more than 4 generations. In this case
control mice came from WT breeding pairs from the
same colony as the hph-1 mice. Genotyping was con-
ducted as previously described [13]. Homozygous and
heterozygous progeny were fertile in both sexes with a
normal litter size. Moreover, a gross preliminary examin-
ation of general health revealed that hph-1 mice mutants
were healthy animals with a normal body weight
compared to WT mice (Table 2).
Experiments were performed on 7–12 weeks-old male
mice, housed in colony cages in temperature-controlled
Nasser et al. Molecular Pain 2013, 9:5 Page 11 of 14
http://www.molecularpain.com/content/9/1/5environments, with unrestricted access to standard diet
and tap water, and kept on a 12:12 h light–dark cycle.
The behavioural tests were conducted during the day-
light hours. Experiments were performed according to
the ethical guidelines for the investigation of experimen-
tal pain with conscious animals [40], and were approved
by the Danish Animal Experiments Inspectorate, Ministry
of Food, Agriculture and Fisheries (No. 2009/561-1622).
The experimenter was blinded to the animal genotypes
during all experimental procedures.
Determination of BH4 in plasma
BH4 was determined by isocratic HPLC analysis as the
difference in biopterin (stable oxidation product of BH4)
after acidic and basic oxidation with iodine [41]. Orbital
blood was collected in tubes containing 10 μl of 180 mg/
ml K2-EDTA (Sigma-aldrich) and 25 μl of 4% (w/v)
dithiothreitol (Sigma-aldrich). Samples were then stored
at room temperature for 3 h and protected from light
before centrifugation at 2650 × g for 20 min [41]. The
plasma samples were stored at – 80°C until analysis.
Samples were then oxidised with a mixture of 1%
(w/v) I2 (AppliChem, Kongens Lyngby, Denmark) and
2% (w/v) KI (Merck KGaA, Copenhagen, Denmark) in
either 1 M HCl or 1 M NaOH for 1 h in the dark and at
room temperature. Excess iodine was reduced by
addition of 5% (w/v) ascorbic acid (Sigma-aldrich). The
oxidised samples were centrifuged in Amicon Ultra Cen-
trifugal filters (Ultracel –10 k; Millipore) at 5000 × g for
30 min. Biopterin content was determined in duplicate
by reverse phase HPLC with fluorescence (Waters 474
Scanning Fluorescence Detector, Milford Massachusetts,
USA) using a Nucleosil 100 C18 analytical column
(5 μm, L × ID 250 × 4.6 mm; Varian) in conjunction
with a pre-column (Nucleosil 100 C18 5 μm, ID 4.6 mm;
Varian). The mobile phase consisted of 10 mM KH2PO4
in 5% (v/v) methanol (HPLC gradient grade; Sigma-
aldrich) with pH adjusted to 4.5. The sample was
injected in a volume of 20 μL and the analysis was run
at a flow of 1 ml/min at ambient temperature. The peak
area was used to quantify biopterin in comparison with
external standards.
Motor behavioural tests
The hanging wire test was performed using a wire cage
lid, and the latency (sec) to fall off the wire lid was
determined during 120 sec. Hind-paw clasping was
tested to evaluate whether the mutation exhibited dys-
tonic posture of the hind-paws. Each mouse was picked
up by its tail and suspended for 15 sec to observe hind-
paw clasping as previously described [42]. The rotarod
test was used to test motor coordination and balance
using an ENV-575 M Five Station RotaRod Treamill
USB-Mouse (Med Associates inc., St. Albans, Vermont,USA). Mice were placed on an elevated rod (3.2 cm
diameter) beginning its acceleration at 3.5 rpm and
ending at 35 rpm over 5 min. Prior to testing, mice were
trained for at least three times. Between trials animals
were allowed to rest for 15 min. The time in sec on the
rotarod and the rotation speed was recorded. Time
periods where mice were passively rotating with the rod
was subtracted.
Hot plate test
Acute heat sensitivity was tested using a Hot Plate Anal-
gesia Meter (Harvard Apparatus, Edenbridge, UK) as
described by Eddy and Leimbach with few modifications
[43]. On the day of testing, mice were allowed to habitu-
ate in their home cages for 60 min in the test room.
After habituation, each mouse was placed one at a time
in a transparent Plexiglas cylinder (13 cm high; diameter
19 cm) on a metal plate preheated to 52 or 55 ± 0.1°C,
and observed until they responded by either hind-paw
licking, lifting or flinching (whichever came first). Fore-
paw licking and lifting are common grooming responses
and therefore not defined as nociceptive behaviour. The
animals were removed immediately after showing a noci-
ceptive response and were only tested once. A cut-off
time of 40 sec was used to prevent tissue damage. The
latencies to respond were taken for statistical analysis.
Hargreaves test
Heat sensitivity to noxious stimuli was assessed with a
plantar test device (Model 400 Heated Base from IITC
Inc, Woodland Hills, Ca, USA) using the method of
Hargreaves et al. [44]. Each mouse was placed in a
square opaque Plexiglas chamber (12 cm high; 10 × 10 cm)
on a glass surface (1.2 cm thick) at room temperature. The
animals were first allowed to habituate for at least 60 min
before measurements began. A mobile radiant heat source
(located approximately 6 cm below the glass surface) was
then aimed at the middle plantar surface of the hind-paw,
and the heat stimulus was applied until the mouse made a
clear nocifensive withdrawal of the paw. Testing during
grooming or exploratory behaviour was avoided [45]. The
intensity of the heat source was adjusted to 22% of max-
imal intensity ≈ 80.89 ± 0.6 mW/cm2. Each mouse was
tested three times, and at least 1 min was allowed between
consecutive measurements in the same paw. The heat sen-
sitivity is expressed as the mean withdrawal latency time
(sec). A cut-off latency time of 20 sec was used. Baseline
measurements were obtained from each animal for at least
2 consecutive days prior to inflammation or sensitisation.
von Frey test
Mechanical sensitivity was measured using von Frey
monofilaments (ranging from 0.008 to 2.0 g, North
Coast Medical Inc., Morgan Hill, Ca, USA) by the up-
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mechanical sensitivity is recorded as 50% threshold
(in grams), the force of the monofilament to which the
animal responds in 50% of the stimuli. Each mouse was
placed in an individual red Plexiglas cylinder (7.3 cm
high; diameter 7.5 cm) on an elevated wire mesh floor
(0.65 × 0.65 cm) allowing access to the plantar surface
of the hind-paws. The animals were allowed a habitu-
ation period of at least 60 min. von Frey monofilaments
were then applied perpendicularly to the middle plantar
surface with sufficient force to cause filament bending
and held for approximately 5 sec or until the hind-paw
was withdrawn, defining a positive response. Lifting the
hind-paw due to normal locomotory behaviour was
ignored, and testing during deep sleep, grooming and
exploring was avoided [45]. Baseline measurements to
mechanical stimuli were performed in each animal for at
least 2 consecutive days prior to inflammation or
sensitisation.
Randall Selitto test
Mechanical pain behaviour was measured using a
Randall Selitto device (IITC Life Science Inc., Victory
Blvd Woodland Hills, CA, USA). Briefly, mice were
allowed to habituate in their home cages for 60 min in
the test room. Each mouse was then placed one at a
time in a transparent restrainer for at least 5 min before
the application of increased pressure to the tail. Mice
were tested three times on different locations starting
from the middle of the tail to the root. At least 3 min
was allowed between consecutive measurements. A
cutoff of 300 g was used. The mechanical sensitivity is
expressed as the mean withdrawal latency in grams.
CFA-induced inflammatory pain
Persistent inflammatory pain was induced by injection of
CFA (1 mg/ml Mycobacterium tuberculosis, Sigma-aldrich)
into the hind-paw of mice. The mice were lightly
restrained using a piece of cloth and 20 μl of CFA suspen-
sion was subcutaneously (s.c.) injected into the plantar sur-
face of the right hind-paw using a GASTIGHTW 50 μl
microsyringe (Hamilton Company, VWR, Denmark) with
a 301/2-gauge needle. Mechanical hypersensitivity after
peripheral inflammation was then tested 1, 2, 4, 6, 8 and
12 days after injection, whereas heat hypersensitivity was
tested 1, 2, 4, 6, 8 and 10 days after paw inflammation as
described above. Paw thickness (mm) was measured after
24 hours using a digital caliper.
Formalin test
Spontaneous nociceptive pain behaviours in response to
chemical stimulation were measured using the formalin
test described by Hunskaar et al. [47], with some
modifications. Mice were placed within a glass cylinder(diameter 10.5 cm), and allowed to habituate for 60 min
before behavioural testing began. Angled mirrors were
placed behind and beside the glass cylinder to allow for
an unimpeded view of the paws. After habituation, 20 μl
of 0.5 or 2.5% (v/v) formalin solution (in isotonic saline)
was injected into the right hind-paw as described above.
The mice were immediately returned to the glass cylin-
der and a timer started to mark the beginning of the
observation period. The total time spend licking/biting
the right hind-paw during 60 min was measured with a
stopwatch and recorded to the nearest second in 5 min
intervals.
Capsaicin test
Injection of capsaicin into the hind-paws of animals
evokes spontaneous pain behaviour and hypersensitivity
to mechanical and heat stimuli. Spontaneous nociceptive
pain behaviours in response to capsaicin injection were
measured as described by Sakurada et al. [48], with some
modifications. The experimental procedure is similar to
the formalin test described above. After habituation
10 μl of 1 μg/paw of capsaicin (Sigma-aldrich, Brøndby,
Denmark) in 0.5% (v/v) ethanol and isotonic saline was
injected s.c. into the plantar surface of the right hind-
paw. The total time spend licking, biting and lifting the
injected paw during 10 min was measured with a stop-
watch and recorded to the nearest second.
Hypersensitivity to heat and mechanical stimuli was
determined as described by Gilchrist et al. [49], with
some modifications. Capsaicin 0.25, 0.5 or 1 μg/paw was
injected s.c. into the plantar surface of the paw. Hyper-
sensitivity was then tested at 15, 30, 45 and 60 min after
capsaicin injection. Heat hypersensitivity was measured
at the site of injection, whereas mechanical hypersensi-
tivity was determined approximately 2 mm from the site
of capsaicin injection.
In preliminary pilot studies (not shown), vehicle
injections did not induce significant pain-like behaviours
in the capsaicin test as well as the CFA and formalin
pain models. Hence, in this study vehicle controls were
not included.
Data analysis
The concentrations of BH4 in plasma are expressed as
nmol/L biopterin. Dihydrobiopterin (BH2), involved in
the regeneration of BH4 (see Additional file 1), can also
be oxidised to biopterin. During acidic oxidation both
BH2 and BH4 are converted to biopterin, whereas basic
oxidation involves the oxidation of BH2 only. Hence, the
actual levels of BH4 are calculated as the difference in
biopterin levels between acidic and basic oxidation.
The CFA and capsaicin data are expressed as relative
pain behaviour. Each mouse was normalised to its own
baseline value, i.e. expressed as index values with the
Nasser et al. Molecular Pain 2013, 9:5 Page 13 of 14
http://www.molecularpain.com/content/9/1/5baseline value defined as 1.0 for each mouse. Data were
analysed using either unpaired t-test, one-way analysis of
variance (ANOVA) or two-way repeated measured ana-
lysis of variance (RM-ANOVA) followed by pair-wise
comparisons on the predicted means using the Fisher’s
LSD test. Area under curve analysis was conducted
using the trapezoidal rule. Statistical transformations
were done where appropriate to meet the requirement of
normal distribution and/or equal variances. The Mann–
Whitney test was performed where appropriate. Data are
presented as mean ± SEM or + SEM. p values less than
0.05 were considered significant. Statistical analysis was
performed using SigmaPlot 11.0 (Systat Software Inc.) or
GraphPad Prism 4.03 (GraphPad Software Inc.).
Additional files
Additional file 1: De novo pathway of BH4 biosynthesis and its
functions. BH4 synthesis proceeds from GTP via three steps catalysed
by GTPCH1, PTS and SR. BH4 is an essential cofactor for the aromatic
amino acid hydroxylases (PAH, TH and TPH) as well as for all isoforms of
NOS. The regeneration pathway involves two steps catalysed by PCD
and DHPR. The red line indicates the enzyme targeted in the hph-1
mouse model. Abbreviations: GTPCH1, GTP cyclohydrolase 1; PTS,
6-pyruvoyltetrahydrobiopterin synthase; SR, sepiapterin reductase; PAH,
phenylalanine hydroxylase; TH, tyrosine hydroxylase; TPH, trypthophan
hydroxylase; NOS, nitric oxide synthase; AADC, aromatic L-amino acid
decarboxylase; PCD, pterin-4-acarbinolamine dehydratase; DHPR,
dihydropteridine reductase.
Additional file 2: Intact paw thickness in hph mice following CFA
injection. The dorsal-plantar paw thickness was measured using a digital
caliper. A significant increase in paw thickness was found in both
genotypes as compared with baseline values (n = 5). WT: ***p < 0.001
and hph: †††p < 0.001. No significant difference was found between
genotypes (p > 0.05). Two-way RM-ANOVA with pair-wise comparisons
using the Fisher’s LSD test. Data are presented as mean + SEM.
Additional file 3: No heat hypersensitivity was observed following
capsaicin injection in both WT and hph mice. Heat sensitivity was
examined before as well as 15, 30, 45 and 60 minutes after intraplantar
injection of capsaicin. Capsaicin did not induce heat hypersensitivity in
both WT and hph mice (p > 0.05, n = 4). Two-way RM-ANOVA with pair-
wise comparisons using the Fisher’s LSD test. Data are presented as
mean ± SEM.
Abbreviations
Hph-1: Hyperphenylalaninemia 1; BH4: Tetrahydrobiopterin;
BH2: Dihydrobiopterin; GTP-CH1: Guanosine triphosphate cyclohydrolase 1;
NOS: Nitric oxide synthase; NO: Nitric oxide; DRG: Dorsal root ganglion;
DAHP: 2,4-diamino-6-hydroxypyrimidine; PP: “Pain-protective”; WT: Wild type;
HPLC: High performance liquid chromatography; DRD: DOPA-responsive
dystonia; CFA: Complete Freund’s adjuvant; TRPA1: Transient receptor
potential cation channel subfamily A member 1; TRPV1: Transient receptor
potential cation channel subfamily V member 1.
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